Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Medicine's Not-So-Silent Killer: Studies Under Scrutiny

Ivanhoe Broadcast News


PORTLAND, Ore. (Ivanhoe Newswire) -- Each year, $84 billion is spent on drug development. The rush to create better pills and more effective medicine could be costing the people who take them more than their money -- it could cost them their health. Is medicine losing out to the almighty dollar? Are clinical trials rigged? The results skewed?

There's a lot on the line. The prescription drug market is a $162 billion dollar a year business. But some say the studies done to get these drugs to market can -- and are -- being manipulated.

Text Continues Below



"Negative studies? We dont hear about them," Peter Lurie, M.D., Deputy Director of Public Citizen's Health Research Group, told Ivanhoe.

Many medical journals are becoming marketing instruments for the drug companies," Sidney Wolfe, M.D., Director of Public Citizen's Health Research Group, said.

A new study finds 2 percent of scientists admit they have fabricated, falsified or altered data to improve the outcome at least once. About 35 percent admit to questionable research practices. A JAMA study reveals that 30 percent of the original research studied was either false or exaggerated. Problems include small study size, design flaws, publication bias and failure to publish negative results.

"A smart drug company -- maybe not an ethical one, but a smart one -- might decide to publish only those studies that put its drug or device in the best light," Dr. Lurie said.

Case in point: $25 billion worth of statins are sold each year to help lower cholesterol. Pharmaceutical companies are racing to create a new improved product.

Every statin company is trying to make people believe their statin is better than another one," Dr. Wolfe said.
 
After astronaut and flight surgeon Duane Gravelines cholesterol went up from 230 to 270, NASA doctors put him on Lipitor. An under-reported side effect changed his life

I didnt know my wife, and I didnt know my home," Graveline told Ivanhoe.

Graveline was suffering from transient global amnesia.

The doctors said, no, no, no, statins dont do that," Graveline said.

Graveline found studies -- not widely reported -- that show statins impact cholesterol in your brain that affects memory.

In our attempt to control the blood cholesterol, the statin drugs were adversely affecting the brain," he added.

Graveline found about 1,000 cases of amnesia reported to the FDA.

Not one of these has ever been reported back to the medical community," he said."

Erick Turner was a doctor who reviewed trials for the better part of his career. When he became a reviewer for the FDA, he got the surprise of his life.

I, first of all, was shocked at the number of negative trials, because I had never seen a negative trial before," Dr. Turner, Senior Scholar at the Center for Ethics and Health Care at Oregon Health and Science University in Portland, told Ivanhoe. "I had been clueless These were studies that simply werent getting published, or perhaps they were being presented in a way that made them look positive."

A JAMA study found industry-sponsored research was positive 87 percent of the time compared with 65 percent of non-industry-sponsored research. UCLA professor Jerome Hoffman says its not just the companies that profit from positive results.

"The financial success of medical journals, particularly the major journals, is intimately tied to meeting the needs of the companies that sponsor these big studies," Dr. Hoffman told Ivanhoe.

The push is on for more disclosure. This year the New England Journal of Medicine now requires authors to disclose any patents or royalties related to their research and it publishes the information with the studies. JAMA and other journals have followed suit. Many believe this is the first step to fixing the problem.

No study is perfect," Dr. Hoffman said. "The large majority come to conclusions that can be questioned."

Those inaccuracies and misrepresentations can end up costing lives.

Some researchers believe the only way to completely fix the problem is to take private funds out of research. The down side to that? Private companies have more money to spend on research than the federal government. Others are pushing for a drug trial registry that would allow the public to see if any trials ended with negative results.

More Information


Click here for additional research on Studies Under Scrutiny

Click here for Ivanhoe's full-length interview with xxxxxdr

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com

FOR MORE INFORMATION, PLEASE CONTACT:

Public Citizen
http://www.citizen.org

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 7/3/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake






About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy